Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Name:
PIIS0959804917314867.pdf
Size:
1.014Mb
Format:
PDF
Description:
Open access full text article
Authors
Valpione, SaraCarlino, M
Mangana, J
Mooradian, M
McArthur, G
Schadendorf, D
Hauschild, A
Menzies, A
Arance, A
Ascierto, P
Di Giacomo, A
de Rosa, F
Larkin, J
Park, J
Goldinger, S
Sullivan, R
Xu, W
Livingstone, E
Weichenthal, M
Rai, R
Gaba, L
Long, G
Lorigan, Paul C
Affiliation
The Christie NHS Foundation Trust, and University of Manchester, Manchester, UKIssue Date
2018-01-19
Metadata
Show full item recordAbstract
Most metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to genetic changes, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse retrospectively outcomes for patients retreated with BRAF-directed therapy.Citation
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. 2018, 91:116-124 Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2017.12.007PubMed ID
29360604Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2017.12.007
Scopus Count
Collections
Related articles
- BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma.
- Authors: Cybulska-Stopa B, Rogala P, Czarnecka AM, Galus Ł, Dziura R, Rajczykowski M, Kubiatowski T, Wiśniewska M, Gęga-Czarnota A, Teterycz P, Ziobro M, Suwiński R, Mackiewicz J, Rutkowski P
- Issue date: 2020 Oct
- Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
- Authors: Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R, Dermatology Cooperative Oncology Group (DeCOG)
- Issue date: 2014 Jan
- Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.
- Authors: Hassel JC, Buder-Bakhaya K, Bender C, Zimmer L, Weide B, Loquai C, Ugurel S, Slynko A, Gutzmer R, German Dermatooncology Group (DeCOG/ADO)
- Issue date: 2018 Jan
- Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
- Authors: Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S
- Issue date: 2014 Dec
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.
- Authors: Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D
- Issue date: 2015 Dec